查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球鳞状细胞癌市场-2022-2029
市场调查报告书
商品编码
1129239

全球鳞状细胞癌市场-2022-2029

Global Cutaneous Squamous Cell Carcinoma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

鳞状细胞癌非侵入性诊断技术的增加预计将推动市场增长。

晚期 cSCC 的诊断涉及多学科专家，包括皮肤科医师、解剖病理学家、外科医生、放射肿瘤科医师和内科肿瘤科医师，可以对患者进行更全面的评估。非侵入性光学诊断技术越来越多地用于临床环境中，以提高诊断准确性并在手术或活检之前对体内肿瘤进行表征。 cSCC 的主要特征，例如聚集的血管模式、肾小球血管和角化过度，可以通过皮肤镜检查确认。反射共聚焦显微镜显示表皮棘状颗粒层异常蜂窝状和无序图案、表皮圆形有核明亮细胞和圆形真皮静脉。此外，皮肤镜检查更常用于色素性病变而不是非色素性病变，用于对不明确病例的鑑别诊断。因此，上述描述有望推动市场的增长。

限制

在预测期内，治疗成本上升、治疗成本无法报销、并发症增加以及疾病早期发现不足被认为是阻碍市场发展的因素。

行业分析

鳞状细胞癌市场根据波特五力、供应链分析、报销方案、管道分析、产品创新和定价分析等各种行业因素对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。由于封锁，对流行病的医疗和外科手术干预已被推迟。此外，没有感染新冠病毒的患者的非紧急医疗就诊被取消或推迟，人们因害怕感染病毒并进一步加重系统压力而不愿联繫卫生服务机构。因此，全球癌症诊断率有所下降，尤其是皮肤恶性肿瘤。例如，荷兰的一项研究发现，从 2 月底到 2020 年 4 月初，所有恶性肿瘤的每週癌症诊断率下降了 27%，皮肤癌的诊断率下降了 61%。

此外，大流行还会扰乱供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上述陈述来看，市场受到了影响，但随着经济活动的恢復，预计将迅速获得牵引力。

全球鳞状细胞癌市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页内容。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 鳞状细胞癌无创诊断技术的兴起有望推动市场增长。
    • 限制因素
      • 在预测期内，飙升的治疗成本预计将成为抑制因素。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章诊断领域

  • CT
  • 核磁共振
  • 活检
  • 其他

第 8 章按治疗类型

  • 手术治疗
    • 莫氏显微手术 (MMS)
    • 刮宫术/电极烧灼术
    • 切除手术
    • 冷冻手术
    • 激光手术
    • 其他
  • 非手术治疗
    • 免疫反应改善剂（外用
      • 咪奎莫特
      • 要求
    • 化疗
    • 药物治疗
      • Keytruda（派姆单抗）
      • Ribtaiyo (semiprolimab)
      • 其他
    • 放射治疗
    • 光动力疗法 (PDT)
    • 全身化疗
    • 其他
  • 其他

第 9 章按治疗方法销售

  • 最终用户
    • 医院
    • 门诊手术中心
    • 诊断中心
    • 其他
  • 销售渠道
    • 医院药房
    • 零售药房
    • 在线药店
    • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • Regeneron Pharmaceuticals, Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Sanofi
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited
  • iNova Pharmaceuticals
  • Bristol-Myers Squibb Company
  • LGM PHARMA
  • Hikma Pharmaceuticals PLC
  • 3M Health Care Limited

第 13 章全球鳞状细胞癌市场-DataM

简介目录
Product Code: DMPH5778

Market Overview

Cutaneous Squamous Cell Carcinoma Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 7.2 % during the forecast period (2022-2029).

Cancer starts in the cells that make up the epidermis (the outer layer of the skin). It commonly develops in parts of the skin that have been exposed to long periods of natural or artificial sunlight (such as from tanning beds). The face, ears, lower lip, neck, arms, and backs of the hands are examples of these locations. It can also happen if you've had your skin burned or exposed to chemicals or radiation. A hard red bump, a scaly red patch, an open sore, or a wart that crusts or bleeds easily can all be signs of cutaneous squamous cell carcinoma. Squamous cell carcinoma of the skin that hasn't spread can typically be cured.

Market Dynamics

Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.

Diagnosis of advanced cSCC involves experts from different specialties, including dermatologists, anatomical pathologists, surgeons, radiation oncologists, and medical oncologists, thereby enabling a more comprehensive patient assessment. Noninvasive optical diagnostic techniques are increasingly used in clinical practice to increase diagnostic accuracy and characterize tumors in vivo before surgery or biopsy. The primary characteristics of cSCC, such as clustered vascular patterns, glomerular vessels, and hyperkeratosis, can be identified through dermoscopy. Reflectance confocal microscopy can reveal aberrant honeycomb or disorganized patterns in the epidermis' spinous-granular layer, round nucleated brilliant cells in the epidermis, and round dermis veins things. Moreover, dermoscopy is used more commonly in pigmented lesions than in non-pigmented lesions in the differential diagnosis of equivocal cases. Thus, from the above statements, the market is expected to drive market growth.

Restraint:

The high cost of the treatment, lack of reimbursement for the treatment, increase in complications rate, and lack of early detection of the diseases are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The cutaneous squamous cell carcinoma market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, pipeline analysis, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Medical and surgical operations for prevalent ailments have been delayed due to the lockdown. Moreover, Non-COVID patients had non-urgent medical visits canceled or postponed, and people were hesitant to contact healthcare services for fear of getting the virus and burdening the system further. This has resulted in a decrease in cancer diagnoses worldwide, particularly in skin malignancies. For instance, a Dutch study found a decline in weekly cancer diagnoses of up to 27% for all malignancies and 61% for skin cancers between the end of February and the beginning of April 2020.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgical segment is expected to hold the largest market share in cutaneous squamous cell carcinoma market

The surgical segment is expected to dominate in 2021. Most squamous cell carcinomas of the skin can be eliminated with minimal surgery or, on rare occasions, with a topical medication. The size, location, and aggressiveness of the tumor matter. For instance, Based on excellent cure rates and low recurrence rates reported in retrospective assessments of initial and recurrent cSCC, Mohs micrographic surgery (MMS) might be the best approach for high-risk patients. Moreover, if skin cancer is very small and has a low risk of spreading, less invasive treatments are the treatment choice. For instance, Curettage and electrodessication (C and E) treatment involves removing the skin cancer surface with a scraping instrument (curet) and then searing the base of the cancer with an electric needle. This treatment is often used for small or very superficial squamous cell skin cancers. Therefore, there is an increase in the demand for surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global cutaneous squamous cell carcinoma market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cutaneous squamous cell carcinoma, advancements in the treatment, well-established infrastructure and product launches and collaborations by the key players are some factors the market is expected to boost in the forecast period. For instance, Cutaneous squamous cell carcinoma (CSCC, also called squamous cell carcinoma of the skin) is the second most common form of skin cancer and five times more prevalent than melanoma in the U.S. Moreover, according to the American Cancer Society, Of nonmelanoma skin cancers, approximately 80% are basal cell carcinoma (BCC), and 20% are squamous cell carcinoma (SCC). In addition, Regeneron Pharmaceuticals, Inc. announced its intention to buy Sanofi's stake in the Regeneron and Sanofi collaboration on Libtayo (cemiplimab) on June 2, 2022 giving Regeneron exclusive global development, commercialization, and manufacturing rights to the medicine.

Furthermore, Merck & Co., Inc. received FDA approval for pembrolizumab (KEYTRUDA) in June 2020. The drug is approved to treat recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) resistant to surgery or radiation. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the cutaneous squamous cell carcinoma market are Regeneron Pharmaceuticals, Inc., Sanofi, Merck & Co., Inc., Mayne Pharma Group Limited, iNova Pharmaceuticals, Bristol-Myers Squibb Company, LGM PHARMA, Hikma Pharmaceuticals PLC, 3M Health Care Limited

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology business based in New York's Westchester County. The business was established in 1988. The company began by studying neurotrophic factors, and their regenerative abilities, hence its name, and subsequently expanded to include cytokine and tyrosine kinase receptor research. Currently, the company engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

LIBTAYO (cemiplimab-rwlc) injection: LIBTAYO is indicated for treating patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

The global cutaneous squamous cell carcinoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing noninvasive diagnostic techniques for Cutaneous Squamous Cell Carcinoma is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high costs of treatment are expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. CT
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. MRI
  • 7.4. Biopsy
  • 7.5. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Surgical*
    • 8.2.1. Moh's Micrographic Surgery (MMS)
    • 8.2.2. Curettage and electrodesiccation
    • 8.2.3. Excisional surgery
    • 8.2.4. Cryosurgery
    • 8.2.5. Laser surgery
    • 8.2.6. Others
    • 8.2.7. Introduction
    • 8.2.8. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Non-surgical
    • 8.3.1. Topical Immune Response Modifiers
      • 8.3.1.1 Imiquimod
      • 8.3.2.1Resiquimod
    • 8.3.2. Chemotherapy
    • 8.3.3. Medications
      • 8.3.3.1 Keytruda (Pembrolizumab)
      • 8.3.3.2 Libtayo (Cemiplimab-rwlc)
      • 8.3.3.3 Others
    • 8.3.4. Radiotherapy
    • 8.3.5. Photodynamic therapy (PDT)
    • 8.3.6. Systemic Chemotherapy
    • 8.3.7. Others
  • 8.4. Others

9. By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales Segment
  • 9.2. End user*
    • 9.2.1. Hospitals
    • 9.2.2. Ambulatory Surgical Center
    • 9.2.3. Diagnostic Centers
    • 9.2.4. Others
    • 9.2.5. Introduction
    • 9.2.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Regeneron Pharmaceuticals, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Merck & Co., Inc.
  • 12.4. Mayne Pharma Group Limited
  • 12.5. iNova Pharmaceuticals
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. LGM PHARMA
  • 12.8. Hikma Pharmaceuticals PLC
  • 12.9. 3M Health Care Limited

LIST NOT EXHAUSTIVE

13. Global Cutaneous Squamous Cell Carcinoma Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us